FDA approves oral therapy for Grade 2 IDH-mutant glioma
Drug Discovery World
AUGUST 8, 2024
. “Today’s approval of Voranigo is an enormous leap forward in cancer care, and a defining moment for people living with Grade 2 IDH-mutant glioma,” said Arjun Prasad, Chief Commercial Officer, Servier Pharmaceuticals.
Let's personalize your content